Research into Novartis' Aurograb treatment designed to combat bacterial infections such as the deadly MRSA bug is being halted by the company after disappointing clinical tests.
The Swiss pharmaceutical giant said in a statement that it had decided to halt the programme "after Phase II results showed a lack of efficacy as an add-on therapy for life-threatening bacterial infections."
Drug-resistant Super Bugs may Arise from Broad Spectrum Antibiotics
University of Melbourne researchers suggest that doctors avoid prescribing expensive broad-spectrum antibiotics for pneumonia to avoid the development of more drug-resistant super bugs.
Advertisement
Novartis will take an impairment charge of 235 million dollars (159 million euros) in the third quarter as a result.
MRSA has shot to prominence in recent years as many people catch the bug while being treated in hospitals -- leading to doctors in Britain being banned from wearing their traditional white coats in favour of plastic aprons in a bid to reduce the risks of transmission.
![Biochip Production may Speed-up Deadly Disease Diagnosis]( "Biochip Production may Speed-up Deadly Disease Diagnosis")
A way to speed-up the production of biological ''chips'', paving the way for rapid tests for serious diseases and MRSA infections
Last June, the European Centre for Disease Prevention and Control (ECDC) warned that "healthcare-associated infections" such as MRSA, which are resistant to many antibiotics, are "possibly the biggest infectious disease challenge facing the EU."
It said that around three million people in the European Union catch a healthcare-associated infection every year and approximately 50,000 die as a result.
Source: AFP
RAS/L
Biochip Production may Speed-up Deadly Disease Diagnosis
A way to speed-up the production of biological ''chips'', paving the way for rapid tests for serious diseases and MRSA infections
Advertisement
Last June, the European Centre for Disease Prevention and Control (ECDC) warned that "healthcare-associated infections" such as MRSA, which are resistant to many antibiotics, are "possibly the biggest infectious disease challenge facing the EU."
It said that around three million people in the European Union catch a healthcare-associated infection every year and approximately 50,000 die as a result.
Source: AFP
RAS/L
MRSA may Be Controlled by 'Minority Report'-style Display
Researchers at Ben-Gurion University of the Negev (BGU) in Israel have developed a new hand gesture recognition system like the one in the futuristic Tom Cruise movie 'Minority Report'
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest Drug News
R21/Matrix-M, the world's second malaria vaccine is readily deployable, and cost-effective making it prepared for distribution in areas where it is most essential.
The reverse vaccine uses the liver's natural "non-target" signals to prevent autoimmune responses against naturally decaying cells.
The psychedelic market set for remarkable growth, projected to hit $7.2B by 2029 with a strong 55% CAGR.
The study explores whether CDNF could influence the progression of ALS in rodent models and to elucidate the mechanism through which it operates.
Amoxicillin-clavulanate use in acute sinusitis patients is associated with a higher incidence of adverse events.
